| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDC7 |
| Uniprot No | O00311 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-574aa |
| 氨基酸序列 | MEASLGIQMD EPMAFSPQRD RFQAEGSLKK NEQNFKLAGV KKDIEKLYEA VPQLSNVFKI EDKIGEGTFS SVYLATAQLQ VGPEEKIALK HLIPTSHPIR IAAELQCLTV AGGQDNVMGV KYCFRKNDHV VIAMPYLEHE SFLDILNSLS FQEVREYMLN LFKALKRIHQ FGIVHRDVKP SNFLYNRRLK KYALVDFGLA QGTHDTKIEL LKFVQSEAQQ ERCSQNKSHI ITGNKIPLSG PVPKELDQQS TTKASVKRPY TNAQIQIKQG KDGKEGSVGL SVQRSVFGER NFNIHSSISH ESPAVKLMKQ SKTVDVLSRK LATKKKAIST KVMNSAVMRK TASSCPASLT CDCYATDKVC SICLSRRQQV APRAGTPGFR APEVLTKCPN QTTAIDMWSA GVIFLSLLSG RYPFYKASDD LTALAQIMTI RGSRETIQAA KTFGKSILCS KEVPAQDLRK LCERLRGMDS STPKLTSDIQ GHASHQPAIS EKTDHKASCL VQTPPGQYSG NSFKKGDSNS CEHCFDEYNT NLEGWNEVPD EAYDLLDKLL DLNPASRITA EEALLHPFFK DMSL |
| 预测分子量 | 63,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDC7重组蛋白的3篇参考文献(模拟示例，非真实文献)：
1. **《Characterization of human CDC7 kinase activity using recombinant protein》**
- 作者：A. Smith et al.
- 摘要：通过在大肠杆菌中表达并纯化重组人CDC7蛋白，研究其激酶活性及对底物MCM2的磷酸化作用，证实CDC7-DBF4复合物在DNA复制起始中的关键功能。
2. **《Development of a CDC7 inhibitor screening platform based on recombinant CDC7/DBF4 complex》**
- 作者：Y. Tanaka et al.
- 摘要：利用昆虫细胞系统共表达并纯化CDC7-DBF4重组复合物，建立高通量激酶抑制剂筛选模型，发现新型小分子化合物可特异性抑制CDC7活性。
3. **《Structural insights into CDC7 kinase activation by DBF4》**
- 作者：R. Kumar et al.
- 摘要：通过X射线晶体学解析重组CDC7-DBF4复合物的三维结构，揭示DBF4结合诱导CDC7激酶结构域构象变化的分子机制。
4. **《Recombinant CDC7 as a biomarker for cancer cell proliferation》**
- 作者：L. Chen et al.
- 摘要：研究显示，重组CDC7蛋白在多种癌细胞系中高表达，其体外激酶活性与肿瘤细胞增殖率呈正相关，提示其作为癌症治疗靶点的潜力。
(注：以上文献为示例，实际研究中请通过PubMed或专业数据库查询真实文献。)
CDC7 (Cell Division Cycle 7) is a serine/threonine kinase critical for initiating DNA replication during the cell cycle. It functions by forming a complex with its regulatory subunit, DBF4 (also called ASK), to phosphorylate components of the pre-replicative complex (pre-RC), particularly the MCM (minichromosome maintenance) helicase. This phosphorylation event is essential for the activation of replication origins, ensuring proper duplication of genetic material during S phase. Dysregulation of CDC7 has been implicated in genomic instability, a hallmark of cancer, making it a potential therapeutic target.
Recombinant CDC7 protein is produced using biotechnological systems (e.g., E. coli, insect, or mammalian cells) to enable functional studies. Its purified form retains kinase activity, allowing researchers to investigate DNA replication mechanisms, cell cycle checkpoints, and interactions with inhibitors. Notably, CDC7 inhibitors are being explored as anticancer agents, as cancer cells often exhibit heightened dependency on CDC7 for uncontrolled proliferation. Recombinant CDC7 also aids in structural studies, such as crystallography, to map binding sites for drug design.
Despite its role in normal cells, CDC7 overexpression in tumors correlates with poor prognosis, highlighting its dual importance in basic biology and translational medicine. Current research focuses on balancing therapeutic efficacy with toxicity, as systemic CDC7 inhibition may affect healthy proliferating cells. Overall, recombinant CDC7 serves as a vital tool for dissecting replication control and advancing targeted cancer therapies.
×
